US Pharmaceutical Excipients Market to Reach $5.58 Billion by 2035, Driven by Biologics and Advanced Formulations
Key Insights
The US pharmaceutical excipients market is projected to grow from USD 3.08 billion in 2025 to USD 5.58 billion by 2035, at a CAGR of 6.12%.
Fillers and diluents held the largest market share in 2025, while coating agents are expected to be the fastest-growing functionality segment.
Lactose-based excipients dominated by type in 2025, with cellulose-based excipients poised for the highest growth rate through 2035.
The US pharmaceutical excipients market is on a robust growth trajectory, with market size expected to climb from USD 3.08 billion in 2025 to approximately USD 5.58 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.12% from 2026 to 2035, according to a recent market analysis. The expansion is fueled by rising demand for biologics, specialty drugs, and advanced pharmaceutical formulations that require high-performance excipients.
Pharmaceutical excipients — inert ingredients added to drugs to promote stability, bioavailability, manufacturability, and therapeutic activity — can constitute up to 90% of a medicine's formulation, underscoring their critical role in pharmaceutical manufacturing as defined by the United States Pharmacopeia (USP).
Market Drivers: Biologics and Advanced Drug Delivery
The growing demand for advanced drug formulations and biologic therapies is projected to accelerate market growth in the coming years. The increase in sophisticated drug formulations and biologic products is expected to drive excipient consumption across pharmaceutical production processes. Furthermore, the rising adoption of novel drug delivery technologies is anticipated to increase the utilization of functional excipients throughout pharmaceutical product development.
The identification of multifunctional excipients continues to gain demand due to the increasing development of complex oral drug formulations, injectables, and biologic-based drugs. These materials are essential for achieving consistency in formulations for manufacturing and have set high-quality and regulatory requirements.
Regulatory Hurdles and Supply Chain Challenges
Stringent regulatory and quality compliance requirements present a significant restraint on market expansion. Complying with numerous regulations creates higher financial and operational costs, placing particular stress on smaller manufacturers. Additionally, dependence on complex global raw material supply chains is anticipated to create procurement and production challenges.
Opportunities in Continuous Manufacturing
The surging implementation of continuous pharmaceutical manufacturing is expected to create substantial opportunities for market participants. As continuous manufacturing gains traction, it accelerates the usage of excipients that can deliver robust performance and processing efficiency. Increasing investments in digital manufacturing technologies and process optimization efforts are further driving the need for high-purity excipient selection.
Artificial Intelligence Transforming Excipient Selection
Artificial intelligence is reshaping the market by speeding up excipient selection and product development. AI-based models are increasingly used in drug manufacturing to assess the effect of excipients on stability, solubility, dissolution rates, and bioavailability. These technologies aid formulation scientists in identifying optimal excipient combinations while minimizing laboratory iterations. AI can also support sophisticated manufacturing process monitoring, identifying deviations before product quality is compromised.
Functionality Segmentation: Fillers and Diluents Lead
The fillers and diluents segment dominated the market in 2025, reflecting their essential role in nearly every solid oral dosage formulation. These ingredients ensure uniformity of weight, dosage uniformity, and large-scale production capability. Lactose, microcrystalline cellulose, and mannitol remain widely used across prescription and non-prescription medications, with demand further bolstered by rising generic drug production by firms across the US.
The coating agents segment is expected to grow at a significant CAGR from 2026 to 2035, driven by the pharmaceutical industry's increasing focus on advanced dosage performance and patient experience. Coating technologies are now increasingly employed to enhance product stability, protect against moisture, mask taste, and aid in swallowing. The increased development of differentiated drug products is expected to further drive the use of advanced coating technologies.
Excipient Type: Lactose Dominates, Cellulose Rising
Lactose-based excipients held the largest market share in 2025, owing to excellent compressibility and formulation versatility. Lactose is in high demand as a tablet and capsule excipient, for dry powder inhaler dosage forms, and in combination drug products. Its good flow properties enable efficient mass production at high speeds in large commercial facilities.
In a notable development, DFE Pharma (search) launched a sustainability initiative called EcoLact 2030 in 2026, encompassing its portfolio of lactose products with verified value chain traceability. The company reported that CO₂ emissions are 30% lower for this portfolio while maintaining pharmaceutical quality and regulatory compliance.
The cellulose-based excipients segment is expected to grow at a significant CAGR between 2026 and 2035, driven by the expanding pipeline of complex drug products. Manufacturers are using microcrystalline cellulose and derivatives to improve hardness, uniformity, and tablet processing. These materials serve as binders, fillers, and disintegrants, simplifying the formulation process in product development.
Regional Leadership: New Jersey at the Forefront
New Jersey leads the US pharmaceutical excipients market, attributed to the concentrated pharmaceutical manufacturing and research settings in the state. The state hosts a significant number of Contract Development Organizations and Formulation Technology Development Organizations with extensive operations requiring substantial volumes of pharmaceutical excipients. Pharmaceutical companies continue investing in production modernization, quality systems, and advanced product development programs, driving demand for high-performance excipient materials.
Competitive Landscape and Recent Developments
The US pharmaceutical excipients market remains moderately consolidated among global specialty ingredient suppliers. Key players include Ashland (search), Roquette, BASF (search) Pharma Solutions, Evonik (search), DFE Pharma (search), and MEGGLE Pharma (search). Recent competitive activity indicates higher levels of innovation and manufacturing network investment. Roquette's 2025 product expansion focused on pharmaceutical coating technology for oral formulations, while Evonik's drug delivery competencies were strengthened through advanced formulation technology investments.
In May 2026, Novartis announced the opening of a new facility in Morrisville, North Carolina, dedicated to manufacturing active pharmaceutical ingredients (APIs) for solid dosage forms including tablets, capsules, and RNA therapeutics. This expansion brings Novartis's North Carolina presence to five facilities across three sites.
Also in May 2026, CordenPharma, a leading global CDMO, announced an agreement to acquire AmbioPharm (search), a US-based peptide API CDMO operating sites in South Carolina and Shanghai, China. The acquisition is set to enhance CordenPharma's Peptides Platform by adding differentiated peptide manufacturing capabilities, providing customers with flexible options for complex, long, and high-purity peptide APIs.